<DOC>
	<DOCNO>NCT00437359</DOCNO>
	<brief_summary>To investigate benefit postoperative adjuvant therapy use sequential administration hormone , toremifene citrate ( TOR ) anastrozole ( ANA ) , chemotherapy breast cancer .</brief_summary>
	<brief_title>Antiestrogen v Aromatase Inhibitor After Adjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>To investigate benefit postoperative adjuvant therapy use sequential administration hormone , toremifene citrate ( TOR ) anastrozole ( ANA ) , chemotherapy breast cancer . TOR report effective , effective , TAM DFS OS postoperative adjuvant therapy . The incidence rate severity adverse effect similar TAM show two clinical trial , Finnish Breast Cancer Group ( FBCG ) International Breast Cancer Study Group ( IBCSG ) . Although significant difference observe trial , study report TOR produce low number thromboembolism event compare TAM , undesirable side effect see patient treat TAM . Additionally , compare TAM , TOR show less endometrial hypertrophy induce estrogen . Endometrial cancer remain one significant problem associate TAM . A TAM metabolite bind DNA form DNA adduct damage cell . It report TAM expand ability form DNA adduct compare TOR vitro . A recent study compare endometrial cell collect patient TAM TOR administer . The k-ras gene mutation investigate case , show TAM hold high frequency gene mutation . Although still need discuss whether k-ras mutation directly relate development endometrial cancer , TAM seem high risk induce cancer compare TOR . In IBCSG14-93 trial , two chemotherapy protocol study subsequent administration TOR . They doxorubicin cyclophosphamide ( AC ) cyclophosphamide , methotrexate , 5-fluorouracil ( CMF ) . These two chemotherapy protocol administer follow sequence : AC four time follow CMF three time administration TOR . The finding reveal estrogen-receptor ( ER ) positive case , DFS equal 73 % TOR group , 65 % TAM group ; hormone receptor ( HR=0.80 ( 0.57-1.11 ) ; P=0.18 ) . OS find total 88 % TOR group , 84 % TAM group ; HR=0.78 ( 0.48-1.27 ) ; p=0.32 ) . Although significant difference two group , TOR group show somewhat improved survival . Based information provide , consider TAM TOR similar efficacy less adverse effect , trial compare two drug , TOR ANA .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Estrogen Antagonists</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Written consent obtain study participation . Breast cancer diagnose histologically breast remove preserved . Positive ER PR test immunohistochemistry ( IHC ) , enzyme immunoassay ( EIA ) meet criteria institution . HER2 evaluation . Patient Status ( PS ) : 0 1 . Fully functional heart , liver , kidney , bone marrow . More one year since last menstruation test postmenopausal estradiol ( E2 ) folliclestimulating hormone ( FSH ) level base evaluation standard institution . Expected live least three month ( long ) study commencement . Pregnant breast feeding . Bilateral inflammatory breast cancer . Multiple cancer . Lifethreatening metastasis . History serious hypersensitivity . Judged ineligible study study doctor .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>